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Schizophrenia is a heterogeneous group of disorders with unknown etiology. Although
abnormalities in multiple neurotransmitter systems have been linked to schizophrenia,
alterations in dopamine (DA) neurotransmission remain central to the treatment of this
disorder. Given that schizophrenia is considered a neurodevelopmental disorder we have
hypothesized that abnormal DA signaling in the adult patient may result from altered
DA signaling during fetal brain development. Environmental and genetic risk factors
can be modeled in rodents to allow for the investigation of early neurodevelopmental
pathogenesis that may lead to clues into the etiology of schizophrenia. To address this
we created an animal model of one such risk factor, developmental vitamin D (DVD)
deﬁciency. DVD-deﬁcient adult rats display an altered behavioral proﬁle in response to
DA releasing and blocking agents that are reminiscent of that seen in schizophrenia
patients. Furthermore, developmental studies revealed that DVDdeﬁciency also altered cell
proliferation, apoptosis, and neurotransmission across the embryonic brain. In particular,
DVD deﬁciency reduces the expression of crucial dopaminergic speciﬁcation factors and
alters DA metabolism in the developing brain. We speculate such alterations in fetal brain
development may change the trajectory of DA neuron ontogeny to induce the behavioral
abnormalities observed in adult offspring.Thewidespread evidence that both dopaminergic
and structural changes are present in people who develop schizophrenia prior to onset
also suggest that early alterations in development are central to the disease. Taken
together, early alterations in DA ontogeny may represent a core feature in the pathology of
schizophrenia. Such a mechanism could bring together evidence from multiple risk factors
and genetic vulnerabilities to form a convergent pathway in disease pathophysiology.
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INTRODUCTION
Schizophrenia is a severe and chronic psychiatric disorder con-
sisting of a heterogeneous group of symptoms and cognitive
impairments. On the basis of the convergent evidence from
the ﬁelds of epidemiology, imaging and post-mortem analy-
sis, the neurodevelopmental hypothesis and the dopamine (DA)
hypothesis have become two major theories of schizophrenia.
The developmental hypothesis proposes that genetic or environ-
mental factors during critical early periods of brain development
adversely impact on adult mental health (Murray and Lewis, 1987;
Weinberger, 1987). The DA hypothesis proposes that DA dysfunc-
tion is central to the pathogenesis of schizophrenia (Carlsson and
Lindqvist, 1963; Seeman and Lee, 1975; Angrist and Vankammen,
1984; Davis et al., 1991; Laruelle et al., 1996; Abi-Dargham et al.,
1998). Recently, these two theories were revised and integrated
through the substantial evidence that all the developmental risk
factors which increase the risk of schizophrenia, appear to share a
common endpoint or “ﬁnal common pathway”of DA dysfunction
(Di Forti et al., 2007; Murray et al., 2008; Howes and Kapur, 2009).
Clinical studies provide strong evidence of DA dysfunc-
tion in patients. Patients with schizophrenia show increased
amphetamine-induced DA release in the striatum (Breier et al.,
1997; Laruelle and Abi-Dargham, 1999; Laruelle et al., 1999; Abi-
Dargham et al., 2009) and have altered presynaptic DA function,
speciﬁcally increased DA synthesis capacity (Howes et al., 2012;
Fusar-Poli and Meyer-Lindenberg, 2013). These factors are highly
associated with psychosis (Howes et al., 2011a) and are generally
not evident in stable schizophrenia patients that are not acutely
experiencing a psychotic episode (Laruelle et al., 1999; Shotbolt
et al., 2011). However, increased presynaptic DA function can also
be observed during the prodromal phase of the disease (Howes
et al., 2009) and in ultra-high risk subjects who then go on to
develop psychosis (Howes et al., 2011b). Thus, it would appear
that alterations in presynaptic DA function precede the onset
of frank psychosis, suggesting that intervention prior to symp-
tom onset may even offer the potential for preventing disease
onset.
Substantial evidence from animal models indicates that fetal or
perinatal factors can result in long-term alterations in dopamin-
ergic function. For example, animal models designed to examine
obstetric complications, such as fetal or neonatal hypoxia, resulted
in increased DA-mediated behavioral responses, increased DA
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release and elevated basal DA in subcortical regions (Bjelke et al.,
1991; Bernert et al., 2003; Boksa and El-Khodor, 2003; Decker
et al., 2003). Rodent models with prenatal exposure to virus-
like agents (e.g., the synthetic double-stranded RNA, Poly I:C)
that explore the neurobiological correlates of maternal infec-
tion (Meyer et al., 2009) also exhibit increased levels of DA
and DA metabolites and enhanced striatal DA turnover (Ozawa
et al., 2006; Winter et al., 2009). In addition, heuristic evidence
that early dopaminergic alterations can lead to impaired cog-
nition and behavior later in life has also been described. For
example, Kellendonk et al. (2006) have shown persistent deﬁcits
in cognition and altered DA function in a mouse model that
transiently overexpresses DA 2 receptors in the striatum during
development. Thus, abnormal DA signaling early in develop-
ment would appear to produce long lasting impairments in brain
function.
Evidence continues to mount from both epidemiological and
pre-clinical studies to indicate that developmental vitamin D
(DVD) deﬁciency may be also an important developmental risk
factor for schizophrenia. Over the past decade, our studies on
the DVD-deﬁcient rat model ﬁrmly established that DVD deﬁ-
ciency affects brain cell proliferation, differentiation, and gross
brain structure, it also produces long-lasting cellular changes
and alterations in behavior in the adult offspring. In particular,
the DVD-deﬁcient adult offspring display enhanced DA-related
behavioral responses and alterations inDA signaling. Understand-
ing the mechanism of action linking DVD deﬁciency with altered
DA signaling couldprovide clues to sharedpathways underpinning
the pathogenesis of schizophrenia.
In this article, we integrate ﬁndings derived from the DVD-
deﬁcient rat model and schizophrenia to propose that develop-
mental DA dysfunction may be a core factor in the susceptibility
and/or development of schizophrenia (Box 1). We begin with a
concise summary of the epidemiological clues that suggest altered
prenatal/perinatal vitamin D levels increase the risk of developing
schizophrenia. Subsequently we introduce the DVD-deﬁcient rat,
discussing evidence from both early development and in adult
offspring suggesting alterations in DA development and func-
tion. Furthermore, the multiple signaling pathways that may lead
to such DA abnormalities in the DVD-deﬁcient rat are also dis-
cussed. The ﬁnal section reviews how DVD deﬁciency could lead
to long-lasting neuroanatomical, neurochemical, and behavioral
changes that are relevant to schizophrenia, and in particular, DA
dysfunction.
THE EPIDEMIOLOGY OF VITAMIN D AND SCHIZOPHRENIA
Numerous pieces of epidemiological evidence implicate low levels
of maternal vitamin D as a potential risk factor for schizophre-
nia. Firstly, one of the most replicated ﬁndings is that people born
in the winter and spring months of the year have an increased
risk of developing schizophrenia later in life (Torrey et al., 1997b;
McGrath, 1999; Davies et al., 2003), and this risk is larger at
high latitudes that feature greater seasonal ﬂuctuations (Davies
et al., 2003). Secondly, people born in urban areas in compar-
ison with those born in rural environments have an increased
risk of developing schizophrenia (Torrey et al., 1997a; McGrath,
1999). Finally, the incidence of schizophrenia is signiﬁcantly
BOX 1 | Salient points.
• Schizophrenia
Neurodevelopmental disorder associated with altered dopamine
function both prior to and during disease onset
• Developmental vitamin D (DVD) deﬁciency
Associated with increased susceptibility to schizophrenia
• DVD rat model
DVD-deﬁciency in the rat leads to a pattern of altered developmental
and adult dopaminergic function
• Vitamin D and dopamine
Early vitamin D signaling is intrinsically linked with the developing
dopamine system
• Animal models of schizophrenia
Multiple animal models of schizophrenia show alterations in
dopamine development prior to post-adolescent alterations in
behavior
• Dopamine and schizophrenia
Although focus remains tied to dopamine as a common endpoint in
schizophrenia, understanding common dopaminergic origins may
be
higher in the second generation of dark-skinned migrants to
cold countries compared to native-born individuals (Cantor-
Graae and Selten, 2005). Moreover, ﬁrst generation migrants
who arrive as babies or infants also have an increased risk of
schizophrenia (Veling et al., 2011). This risk decreases with the
increasing age of the migrant suggesting early life environmen-
tal conditions are critical. Given that vitamin D deﬁciency is
common (1) during winter and spring, (2) at high latitudes
(Holick et al., 1995), (3) in urban environments (McGrath et al.,
2001) and (4) in dark skinned individuals (Clemens et al., 1982;
Holick et al., 1995), these ecological data led to the hypothesis
that low maternal vitamin D could be a modiﬁed risk factor for
schizophrenia.
The direct analytical evidence in support of this hypothe-
sis has also now been demonstrated. Schizophrenia has been
shown to be ameliorated by vitamin D supplementation in the
1 year of life (McGrath et al., 2004). Most recently, and most
importantly, a Danish population-based case-control study (423
cases and 423 control) that directly assessed vitamin D levels
in blood spots from new born infants provided solid evidence
showing that low prenatal vitamin D levels are associated with
an increased risk of schizophrenia (McGrath et al., 2010). Taken
together, these data support the hypothesis that an absence
of vitamin D during development may lead to an increased
risk of schizophrenia. To establish the biological plausibility of
whether DVD deﬁciency could be related to schizophrenia, our
group established a DVD-deﬁcient rat model which has shown
that low prenatal vitamin D adversely affects brain development
and adult behavior, especially DA development and DA-related
behaviors.
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THE DVD-DEFICIENT RAT MODEL OF SCHIZOPHRENIA
DVD-deﬁcient offspring are produced by feeding female
Sprague-Dawley rats a diet that lacks vitamin D but contains
normal calcium and phosphorous. Rats are maintained on this
diet for 6 weeks, after which and prior to mating, serum vita-
min D3 depletion is conﬁrmed by measuring the stable vitamin
D metabolite 25 hydroxy-vitamin D (25(OH)D3) as <0.34 ng/ml
(Eyles et al., 2009). Vitamin D deﬁcient dams are maintained on
the vitamin D depleted diet until the birth of pups. Control ani-
mals are kept under identical conditions but are supplied with
standard rat chow containing vitamin D3. All dams (both control
and depleted) are kept under standard housing conditions (con-
trol rat chow) after giving birth. Although vitamin D3−depleted
dams and offspring remain normocalcemic, increased parathy-
roid hormone levels have been observed in both the dams and
pups (Cui et al., 2010; Burne et al., 2011). In this model the expo-
sure to vitamin D3 depletion is only transient as all dams are
returned to a normal vitamin D containing diet ate birth. This is
sufﬁcient to replete DVD-deﬁcient offspring to normal vitamin
D3levels by two weeks of age. Importantly, calcium levels in vita-
min D deﬁcient dams and DVD-deﬁcient pups are not altered by
this protocol (Eyles et al., 2006; O’Loan et al., 2007). The acute
effects of DVD deﬁciency including abnormal brain development,
changes in gross brain structure and altered neurochemistry in
addition to persistent alterations in behavior will be discussed in
the following sections.
BRAIN DEVELOPMENT IN THE DVD-DEFICIENT RAT
The idea that DA dysfunction represents the “ﬁnal common
pathway” in schizophrenia (Di Forti et al., 2007; Murray et al.,
2008; Howes and Kapur, 2009) is supported by strong evidence
of abnormal DA signaling in the adult patient, particularly at
the presynaptic level (Howes et al., 2012; Fusar-Poli and Meyer-
Lindenberg, 2013). However, we know little about the up-stream
developmental alterations in DA physiology that may under-
pin these effects. For example, early life risk factors associated
with schizophrenia may change the way DA systems develop.
Thus, increases in presynaptic DA function in individuals who
progress to clinical schizophrenia may result from abnormalities
in the early ontogeny of DA systems. Animal models, such as
the DVD-deﬁcient rat, allow for more thorough investigations
into early developing neurotransmitter systems and early devel-
opmental alterations that lead to behavioral and neurochemical
abnormalities in the adult.
EARLY DOPAMINERGIC ABNORMALITIES
Embryonic DA neuron development is a dynamic process with
multiple factors responsible for normal function. In the rat, dif-
ferentiation of monoamine cells in the substantia nigra (located
in the midbrain) begins as early as embryonic day (E) 11 with
the peak period of DA neuron birth occurring at E12(Lauder and
Bloom, 1974; Gates et al., 2006). Subsequent innervation of the
striatum in the basal ganglia from midbrain monoamine neurons
occurs from E14-17(Voorn et al., 1988). DVD deﬁciency has been
shown to alter the gene expression of key DA speciﬁcation factors
(i.e., factors involved in the phenotypic development of DA neu-
rons) at both of these crucial time-points in DA development. At
E12, coinciding with monoamine cell differentiation, expression
of Nurr1 and p57Kip2 were decreased in DVD-deﬁcient rats (Cui
et al., 2010). Tyrosine hydroxylase (TH; the rate limiting enzyme in
DA synthesis and a reliable marker of DA neurons) also appeared
to be reduced in DVD-deﬁcient embryos at this same time point.
Nurr1 expression was also decreased at E15. This represents a
period when dopaminergic innervation of the striatum begins to
occur. Nurr1 (also known as NR4A2), an orphan nuclear receptor,
is an essential factor in DA neuron development and maturation
(Wallen et al., 2001) and p75Kip2 cooperates with Nurr1 dur-
ing DA cell development (Joseph et al., 2003). Nurr1-deﬁcient
mice show complete DA neuron agenesis (Zetterstrom et al., 1997)
and Nurr1 has been shown to directly activate the TH promoter
gene in cell cultures (Sakurada et al., 1999; Iwawaki et al., 2000;
Kim et al., 2003). Therefore, decreased Nurr1 expression cou-
pled with a trend for reduced TH expression strongly suggests
decreased or delayed DA cell differentiation in DVD-deﬁcient
rats.
These alterations in DA speciﬁcation factors during devel-
opment in the DVD-deﬁcient rat compliment alterations in
DA turnover identiﬁed at birth. Under normal conditions, the
majority of DA metabolism is through intra-neural oxidative
deamination via monoamine oxidase (MAO) to produce dihy-
droxyphenylacetic acid (DOPAC). This is followedby a subsequent
extra-neural O-methylation via catechol-O-methyl transferase
(COMT) to form homovanillic acid (HVA; Westerink, 1985).
DVD-deﬁcient pups show a 45% reduction in brain COMT levels
at birth (Kesby et al., 2009). Moreover, this reduction in COMT
is associated with an increased ratio of DOPAC to HVA, suggest-
ing altered DA turnover. COMT remains an interesting target for
schizophrenia research with less efﬁcient isoforms increasing the
risk of schizophrenia when coupled with adolescentmarijuana use
(Howes and Kapur, 2009). Thus, DVD deﬁciency directly impacts
on factors that are essential in early DA neuron development and
embryonic DA turnover.
GROSS BRAIN ANATOMY, MITOSIS AND APOPTOSIS
The initial absence of vitamin D also affects other, more gen-
eral, aspects of brain development that do not directly relate to
DA neurons. For example, gross brain architecture is different
in that DVD-deﬁcient pups have cerebral hemispheres that are
longer but not wider than control pups (Eyles et al., 2003). Fur-
thermore, when corrections were made for the altered shape of
these brains, the lateral ventricles were larger but the neocortex
thinner than in control pups. Enlarged lateral ventricles have been
observed in patients with schizophrenia and represent one of the
more replicated neuroanatomical ﬁndings in schizophrenia (Chua
et al., 2007; Nakamura et al., 2007; Pagsberg et al., 2007). These
brain anatomical changes were also associated with altered rates
of cellular proliferation.
VitaminD is known to be involved in themodulation of cellular
proliferation and apoptosis in many tissues (Banerjee and Chat-
terjee, 2003; Dusso et al., 2005). In the developing brain, levels
of vitamin D receptor (VDR) expression coincide with increas-
ing levels of apoptosis and decreasing levels of mitosis (Burket
et al., 2003) suggesting similar actions to that seen in peripheral
tissue. Conversely, the absence of vitamin D in the embryonic
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brain results in increased levels of mitosis and decreased levels of
apoptosis (Eyles et al., 2003; Ko et al., 2004). DVD deﬁciency also
altered gene expression proﬁles regulating mitosis and apoptosis
in the brain (Ko et al., 2004). Furthermore, neurosphere cultures
derived from DVD-deﬁcient rat pups result in a greater number
of neurospheres than cultures from control rat pups (Cui et al.,
2007), also suggesting increased cellular proliferation. Thus at
both the cellular and transcriptional levels, vitamin D appears
fundamentally involved in the rate of proliferation and cell death
in the brain. These early alterations in both DA signaling, brain
structure and proliferation in DVD-deﬁcient offspring appear to
produce associated abnormal neurochemistry and behavior in
adulthood.
ALTERATIONS IN ADULT DVD-DEFICIENT OFFSPRING
DOPAMINE-BASED ALTERATIONS
Subcortical DA function is an essential factor with regard to
novelty-induced behavioral activation (Hooks and Kalivas, 1995)
and both novelty and stress (i.e., handling etc.) result in increased
DA release in the prefrontal cortex (PFC; Feenstra et al., 1995).
Moreover, enhanced responsiveness to novelty is associated with
an increased response to agents that enhance synaptic DA lev-
els (Chefer et al., 2003). Adult DVD-deﬁcient rats show enhanced
novelty-induced locomotion on a range of tasks including the
hole board and elevated plus maze (Burne et al., 2004; Kesby et al.,
2006). Interestingly, this enhanced response can be attenuated
in DVD-deﬁcient rats with handling procedures and injections
(Burne et al., 2006; Kesby et al., 2006).
Amphetamine has been shown to induce psychotic-like phe-
notypes in non-psychotic individuals and schizophrenia patients
show enhanced DA release and positive symptoms relative to
healthy individuals after exposure to low doses (Janowsky et al.,
1973; Lieberman et al., 1987; Laruelle et al., 1999). Amphetamine-
induced behaviors in rodents are therefore considered a model
of the psychotic symptoms seen in schizophrenia. Amphetamine
induces DA release in the brain primarily due to actions at the DA
transporter (DAT; Sulzer et al., 1993; Wieczorek and Kruk, 1994;
Jones et al., 1998). Female DVD-deﬁcient rats show an increased
sensitivity to amphetamine-induced locomotion as adults but
not juveniles (Kesby et al., 2010). Although male DVD-deﬁcient
rats do not show an enhanced response after an acute dose of
amphetamine, a similar sensitivity to amphetamine appears to
occur after multiple doses (Kesby et al., 2010). Adult female DVD-
deﬁcient rats also have increased levels of DAT in the caudate
putamen (CPu) and increased afﬁnity for DAT ligands in the
nucleus accumbens (Acb; Kesby et al., 2010) suggesting alter-
ations in DAT function may mediate the enhanced response to
amphetamine.
DVD-deﬁcient rats also show increased sensitivity to the
antipsychotic haloperidol (Kesby et al., 2006). Haloperidol is a
typical antipsychotic used to treat the positive symptoms of
schizophrenia and its antipsychotic potency is directly related to
the blockade of DA 2 receptors (Seeman and Lee, 1975; Creese
et al., 1976). DA 2 receptors however, do not appear to be altered in
DVD-deﬁcient rats (Kesby et al., 2010) indicating the behavioral
response to haloperidol in DVD-deﬁcient rats is more complex
than a simple change in receptor density. Overexpression of DA
2 receptors in schizophrenia appears to have only a small effect
size (Laruelle, 1998; Seeman and Kapur, 2000) and as such is not
necessarily a key feature of the disease even though all antipsy-
chotic drugs target these receptors. Thus, DVD deﬁciency induces
persistent post-adolescent sensitivity to the behavioral effects of
dopaminergic drugs that appears to mirror the post-adolescent
onset of frank psychotic symptoms in schizophrenia patients and
these sensitivities can be attenuated with the use of antipsychotic
drugs.
Aspects of learning and memory are also affected in DVD-
deﬁcient rats. Latent inhibition refers to a learning phenomenon
describing how it takes longer to associate relevance to a familiar
stimulus than a novel stimulus. DVD-deﬁcient rats have impaired
latent inhibition (Becker et al., 2005) suggesting a deﬁcit in the
ability to attend selectively to relevant stimuli. Acutely psychotic
patients also show impairments in latent inhibition (Gray et al.,
1991; LubowandGewirtz, 1995) andDAagonists have been shown
todecrease latent inhibition inhealthy adultmales (Swerdlowet al.,
2003). Moreover, DVD-deﬁcient rats show increased impulsivity
and a lack of inhibitory control when assessed on the 5-choice
continuous performance task (Turner et al., 2013). The increased
impulsivity in DVD-deﬁcient rats can also be attenuated with the
atypical antipsychotic, clozapine. Impulsivity in healthy humans
has been associated with the availability of the DAT (Costa et al.,
2012) and in rats; DA receptors in themedial PFC also appear to be
critical (Pardey et al., 2012). Thus multiple DA-based behavioral
alterations are present in the adult DVD-deﬁcient rat. However,
other neurotransmitter systems, closely linked to the DA system,
also appear to be affected in DVD-deﬁcient rats.
ALTERNATIVE NEUROTRANSMITTER SYSTEM ALTERATIONS
The use of N-methyl-D-aspartic acid (NMDA) receptor antag-
onists such as PCP, ketamine and MK-801 in animal models has
becomemorewidespread because the symptoms elicited in healthy
people are more similar to those seen in people with schizophre-
nia than those observed after amphetamine (Krystal et al., 1994;
Lahti et al., 2001). As a result, NMDA receptor hypofunction
models of schizophrenia have been proposed and are also widely
studied (Olney and Farber, 1995). DVD-deﬁcient rats show a con-
sistently enhanced locomotor response to MK-801(Kesby et al.,
2006; O’Loan et al., 2007; Kesby et al., 2011). Importantly, this
behavioral sensitivity is heavily dependent on the timing of vita-
min D deﬁciency. Vitamin D deﬁciency in the later portion of
gestation is required to elicit this behavioral sensitivity whereas
vitamin D deﬁciency during the early portion of gestation has
no impact (O’Loan et al., 2007). Coincidently, the later portion
of gestation includes active DA neuron migration, differentiation
and innervation in the embryonic brain. Although it is fairly clear
that DA release is not required for the effects of MK-801 on loco-
motion (Carlsson and Carlsson, 1989), DA receptor antagonists
have been shown to attenuateMK-801-induced behavior (Criswell
et al., 1993; Willins et al., 1993; Andine et al., 1999; Kesby et al.,
2006). Consistent with this, the enhanced locomotor response to
MK-801 in DVD-deﬁcient rats is selectively blocked by pretreat-
ment with the DA 2 receptor antagonist haloperidol, at a dose
that does not signiﬁcantly attenuateMK-801-induced locomotion
in control rats (Kesby et al., 2006). This suggests that abnormal
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DA signaling remains a component of the enhanced response to
MK-801 consistently observed in DVD-deﬁcient rats.
In Summary, DVD deﬁciency results in multiple outcomes
in the adult animal that suggest neurotransmission and neuron
integrity may be compromised. In addition, there is strong evi-
dence that the altered response to psychomimetic drugs in adult
DVD-deﬁcient rats appears closely linked to DA function. The
mechanism for how the developmental absence of vitamin D may
inﬂuence DA signaling in the adult remains unknown. However
given the multiple pieces of evidence indicating early alterations
in the ontogeny of DA systems in this model we suspect this may
hold the key.
LINKING DOPAMINE ABNORMALITIES TO DVD DEFICIENCY
EARLY VITAMIN D SIGNALING AND DOPAMINE
Vitamin D is a nuclear steroid. Its signaling is via a single nuclear
receptor called the VDR which is expressed widely throughout
the human (Sutherland et al., 1992; Zehnder et al., 2001; Eyles
et al., 2005) and rat brain (Clemens et al., 1988; Fu et al., 1997;
Prufer et al., 1999). TheVDR shares structural characteristics with
other nuclear steroid receptors (Mangelsdorf et al., 1995). After
ligand binding the VDR forms a heterodimer with the retinoid X
receptor (RXR). This complex binds to vitamin D response ele-
ments (VDRE) in the promoters of a number of genes; to regulate
their transcription (Christakos et al., 2003). Expression of theVDR
begins early in development (Fu et al., 1997; Veenstra et al., 1998;
Erben et al., 2002; Burket et al., 2003; Cui et al., 2013) and increas-
ing levels of VDR coincide with increasing levels of apoptosis and
decreasing levels of mitosis (Fu et al., 1997; Veenstra et al., 1998;
Erben et al., 2002; Burket et al., 2003). However, it is the coincident
expression of the VDR within developing DA neurons (Cui et al.,
2013) and projections in the brain that suggest an important role
for vitamin D in the developing DA system.
Effects of Vitamin D on dopamine differentiation and innervation
Expression of the VDR can be found as early as E12 in the
neuroepithelium (Veenstra et al., 1998) coinciding with the peak
differentiation of monoamine cells in the substantia nigra; the pri-
mary source of midbrain dopaminergic projections to the basal
ganglia (Lauder and Bloom, 1974; Gates et al., 2006). As divid-
ing mesencephalic DA progenitor cells stop proliferating, they
immediately begin to express speciﬁcation factors [initially Nurr1
(Joseph et al., 2003) with p57Kip2 expressed soon after (Wallen
et al., 1999)] that help to establish the neurotransmitter pheno-
type of these cells. DVD-deﬁcient E12 embryos show decreased
gene expression of Nurr1, p57Kip2 and TH (Cui et al., 2010) sug-
gesting altered vitamin D signaling affects early monoamine cell
development, perhaps even prior to E12. Not surprisingly, all three
of these factors are linked and it would appear that Nurr1 is the
upstream effector that results in altered p57Kip2 and TH levels.
For example, Nurr1 has been shown to activate the expression of
p57kip2 which then cooperates with Nurr1 in the maintenance
of DA neurons (Joseph et al., 2003). Moreover, Nurr1 has been
shown to regulate important proteins in DA synthesis and func-
tion including TH, vesicular monoamine transporter 2 (VMAT2)
and DAT (Smidt and Burbach, 2007). Thus a decrease in Nurr1
expression would be expected to result in decreased p57Kip2 and
TH as found in the DVD-deﬁcient embryo.
Monoaminergic striatal innervation occurs from E14-17
(Voorn et al., 1988) with functional release observed at E18
(Nomura et al., 1981). Consistent with the premise that vitamin
D plays a role in dopaminergic cell development, VDR expression
in the differentiating ﬁeld of the midbrain and basal ganglia can
be observed by E15 (Veenstra et al., 1998). Furthermore, DVD-
deﬁcient embryos show decreased expression of Nurr1 at E15
(Cui et al., 2010). Thus, the appearance of the nuclear expres-
sion of the VDR in the mesencephalon at the peak period of DA
neuron differentiation raises the possibility that the absence of
vitamin D at this point may lead to changes consistent with the
absence of this ligand. Namely, increased rates of DA neuron pro-
liferation and delayed differentiation. This is consistent with the
reduction in the expression of post-mitotic speciﬁcation factors
such as Nurr1. Interestingly, although Nurr1 gene expression in
the mesencephalon peaks from E13 to E15 (Volpicelli et al., 2004)
the levels of Nurr1 in the developing rat cortex show a different
temporal window of expression with peak protein levels occurring
later at P1 (Li et al., 2011). Whether the levels of cortical Nurr1
are decreased or delayed as observed in the mesencephalon of
DVD-deﬁcient rats is currently unknown.
How the absence (or presence) of vitamin D could alter
Nurr1 levels remains unknown. However, retinoid function and
speciﬁcally the interactions of retinoid receptors and Nurr1 have
led researchers to suggest that retinoid signaling may be one
link between the genetic and environmental susceptibility to
schizophrenia (Palha and Goodman, 2006). Both Nurr1 and
the VDR form heterodimers with the RXR (Mangelsdorf et al.,
1995; Perlmann and Jansson, 1995; Aarnisalo et al., 2002). Indeed,
signaling through the RXR-Nurr1 heterodimer is involved in
the neuroprotective actions of Nurr1 in DA neurons (Wallen-
Mackenzie et al., 2003). However, in rat neural precursor cells the
RXR-Nurr1 heterodimer has been shown to reduce Nurr1 activ-
ity in DA neuron generation and reduce TH promoter activity
(Yoon et al., 2010). It is important to note that levels of the VDR
are unaltered in DVD-deﬁcient pups (Eyles et al., 2003) allowing
for ligand-independent actions. The interactions between, and
functions of, the VDR and RXR appear to be extremely depen-
dent on the presence of vitamin D. For example, the VDR-RXR
heterodimer with no ligand acts as a weak transcriptional repres-
sor (Tagami et al., 1998). Furthermore, when no ligand is present
the RXR increases the nuclear accumulation of VDR by slowing
nuclear export whereas, when bound to vitamin D, the VDR regu-
lates the import of the RXR into the nucleus (Prufer and Barsony,
2002). Thus the non-ligand bound VDR may lead to decreased
levels of cytosolic VDR and reduced competition for RXR com-
pared with Nurr1. This may lead to an increase in the inhibitory
functions of the RXR-Nurr1 heterodimer on DA neuron genera-
tion (Yoon et al., 2010). Decreased DA neuron generation would
subsequently lead to reduced levels of Nurr1 and TH as found in
DVD-deﬁcient embryos. The presence and interaction of theVDR
(minus ligand) on the availability or function of the RXR-Nurr1
heterodimer is unknown but this remains an intriguing target.
In addition, recent work also suggests that Nurr1 expression
induces the expression of the glial derived neurotrophic factor
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(GDNF) receptor, Ret, in adult nigral DA neurons (Decressac
et al., 2012). The decreased Nurr1 levels may therefore decrease
GDNF signaling in DVD-deﬁcient embryos. Moreover, evidence
continues to accumulate indicating vitamin D positively regulates
GDNF levels in the developingmesencephalon (Orme et al., 2013).
GDNF is an important factor involved in DA neuron develop-
ment, survival and function (Lin et al., 1993; Chun et al., 2002;
Kholodilov et al., 2004). Thus, the combined local expression these
three factors (VDR,RXR, andNurr1) in addition to their coopera-
tive signaling capabilities may be causal for the downstream effects
of DVD-deﬁciency on DA neuron development.
Effects of Vitamin D on postnatal dopamine events
Developing DA neurons undergo two postnatal phases of natural
cell death (Oo and Burke, 1997); the ﬁrst peak is around postnatal
day (P) 2 and the second peak occurs around P14. The combina-
tion of these two phases of cell death determines the number of
DA cells within the adult brain. There are various regulatory fac-
tors involved in this process. For example, the ﬁrst of these stages
is heavily regulated by GDNF levels (Oo et al., 2003) and interac-
tions with striatal targets (Burke, 2004). The second stage is less
well understood but the dependence on striatal targets appears to
remain (Burke, 2004). These processes establish DA neuron num-
ber and functional connectivity in the juvenile animal. Vitamin D
has been shown to increase GDNF synthesis in the brain (Wang
et al., 2000). Given the importance of GDNF in the postnatal pro-
grammed cell death of DA neurons in addition to its roles in DA
neuron development, survival and function (Lin et al., 1993; Chun
et al., 2002; Kholodilov et al., 2004); this represents a potential fac-
tor that could permanently alter key dopaminergic regions that
contribute to adult behavior. We assume the levels of Nurr1 in
DVD-deﬁcient rats would have returned to control levels by this
stage given the trend toward this in embryonic development (Cui
et al., 2010). However, any consequence of earlier Nurr1 signaling
deﬁcits on the expression of the GDNF receptor, Ret, may perse-
vere. Subsequently, this may lead to reductions in GDNF signaling
during these crucial phases of DA cell death in DVD-deﬁcient rats.
TheseDA cell death events are also dependent on the functional
interaction of DA neurons and their striatal targets (Burke, 2004).
Therefore, compromised neuronal signaling after DVD deﬁciency
could potentially impact the survival of DA neurons. For example,
silencing the VDR in cortical cultures from E16 embryos dis-
rupts L-type voltage-sensitive calcium channels which are involved
in calcium homeostasis and neuronal integrity (Gezen-Ak et al.,
2011). Furthermore, DVD-deﬁcient pups also show altered DA
turnover as a result of decreased levels of COMT (Kesby et al.,
2009). Both of these vitamin D-induced alterations could poten-
tially lead to altered signaling in DA neurons. Thus altered DA
signaling at birth suggests that the early postnatal period may
represent an early developmental window whereby permanent
alterations in DA function may lead to altered adult behavior.
AN ALTERED DEVELOPMENTAL TRAJECTORY
Schizophrenia
One key facet of schizophrenia is the post-adolescent onset of
“psychosis” or psychotic symptoms (Delisi, 1992). The wealth of
epidemiological evidence for a neurodevelopmental pathogenesis
as described throughout this review needs to be considered in the
light of the post-adolescent onset of disease (Andreasen, 1995).
The brain undergoes a high level of reorganization throughout
adolescence (Spear, 2000; Andersen, 2003; Adriani and Laviola,
2004). Thus, the normal processes involved in brain maturation
may be compromised such that the reﬁnement of projections and
signaling pathways uncovers or reveals an underlying dysfunc-
tion, such as altered genetic architecture (Lee et al., 2012) or subtle
changes in neurochemical function (Howes et al., 2006; Howes
et al., 2009).
The period of adolescent maturation is of particular impor-
tance to the clinical onset of psychotic disorders such as
schizophrenia. For example, phencyclidine and ketamine (i.e.,
NMDA receptor antagonists) fail to produce hallucinations in pre-
pubertal children, however they routinely do in adults (Hirsch
et al., 1997). Thus the underlying connectivity/neurotransmission
required for these drugs to elicit psychosis analogous to that seen in
schizophreniamay not be functional until after adolescence. Obvi-
ously the presence of early onset schizophrenia suggests that these
same processes can be present prior to adolescence but the fact
remains that subtle alterations in cytoarchitecture, neurotransmis-
sion or brain connectivity may not yield a psychotic phenotype
until these maturational processes are established. Importantly,
the prodromal phase of schizophrenia that overlaps with this
period of maturation is now being linked to dopaminergic abnor-
malities. For example, individuals at ultra-high risk of developing
schizophrenia show increased striatal DA synthesis (Howes et al.,
2006, 2009). There is also both behavioral and structural evidence
that brain development is altered in people prior to disease onset.
For example, behavioral abnormalities, IQ and social deﬁcits have
been described in children who later develop the disease (Ayl-
ward et al., 1984; Done et al., 1994; Ellenbroek and Cools, 1998;
Murray and Fearon, 1999; Cannon et al., 2002, 2006). Moreover,
at the onset of psychosis there are already changes in the gross
anatomy of patients’ brains. For example, the lateral ventricles are
increased in size (Chua et al., 2007; Nakamura et al., 2007; Pagsberg
et al., 2007) and the cortex of schizophrenia patients frequently has
decreased white and gray matter volume (Gur et al., 2000; Pantelis
et al., 2003; Chua et al., 2007; Nakamura et al., 2007; Pagsberg et al.,
2007). More recently two studies have shown that decreases in the
gray matter volume of the parietal cortex and hippocampus pre-
cede the onset of psychosis in prodromal patients (Mechelli et al.,
2011; Dazzan et al., 2012). Thus, there are a number of changes
reﬂecting altered brain development and these appear to be
present well before the onset of the symptoms required for clinical
diagnosis.
Although cases of early onset schizophrenia suggest these ado-
lescent maturational processes are not “key” per se, they still seem
to play a signiﬁcant role. For example, the decreases in corti-
cal thickness found in early onset schizophrenia become more
localized and more akin to those seen in adult onset schizophre-
nia when these patients reach adulthood (Greenstein et al., 2006)
suggesting a role for adolescentmaturation even in thosewith early
onset schizophrenia. Furthermore, these examples also support a
hierarchy of susceptibility in that highly susceptible individuals
may be compromised earlier in life whereas others may require
further extended environmental or developmental stressors to
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elicit frank symptoms. The fact that the enlarged lateral ventricles
in DVD-deﬁcient rats only persist to adulthood when the period
of vitamin D deﬁciency is extended to weaning (Eyles et al., 2003;
Feron et al., 2005) supports a titratable approach to brain sus-
ceptibility. In addition, it also suggests that further study on the
temporal window of vitamin D deﬁciency would be extremely
informative.
Rodent analogs
There are notable similarities between adolescent/sexual mat-
uration in rodents and humans. For example, the course of
sexual maturation in rodents is preceded by the overproduction
of synapses and accompanied by their subsequent elimination
(Andersen et al., 1997). These dynamic changes in receptor density
are thought to reﬂect the focussing and strengthening of synaptic
connections required for adult life. This also occurs in humans
with an estimated loss of almost one-half of the average num-
ber of synapses per cortical neuron over the adolescent period
(Rakic et al., 1994). This period therefore represents a window
whereby external inﬂuences prior to, rather than after, can dif-
ferentially impact on adult brain function in both rodents and
humans (Spear, 2000; Andersen, 2003; Adriani and Laviola, 2004).
Of particular interest to both DVD deﬁciency and schizophre-
nia are the dynamic changes observed in the DA system over this
period. For example, in the rat the density of both D1 and D2
receptors increase in the striatum prior to puberty, followed by
their decline during puberty (Andersen et al., 1997). However, it is
important to note that the development andmaturation of the DA
system is a dynamic process with behavioral and neurochemical
responses continuing to change in rats for years after birth (Hebert
and Gerhardt, 1999; Rutz et al., 2009).
Akin to drug sensitivities and the psychotic symptoms observed
in schizophrenia, postpubertal psychomotor sensitivities to drugs
such as amphetamine and MK-801 have been found in develop-
mental animal models after DVD deﬁciency (Kesby et al., 2010),
gestational disruptions in neurogenesis (Flagstad et al., 2004),
neonatal ventral hippocampal lesions (Al-Amin et al., 2001) and
prenatal Poly I:C administration (Meyer et al., 2008). Taken
together these suggest a myriad of interventions can result in
psychotic-like drug sensitivities that become observable after ado-
lescence. Perhaps themost important aspect of thesemodels is that
they do not include any additional “stressor” during the adoles-
cent period and are the sole results of early life interventions that
alter normal brain development. Early intervention with antipsy-
chotic treatment has already been shown to attenuate structural
and behavioral abnormalities after prenatal Poly I:C administra-
tion (Piontkewitz et al., 2012) emphasizing that the developmental
cascade prior to adolescence is critical to the “schizophrenia phe-
notype.” Furthermore, these models also provide the ability to
investigate developmental abnormalities induced by a range of
interventions and identify the convergent etiological pathways that
result in similar adult behavioral phenotypes.
DOPAMINE: A COMMON ENDPOINT OR A COMMON
BEGINNING
The premise that no single genetic vulnerability or molecular fac-
tor “causes” schizophrenia is well accepted amongst the research
community and is conﬁrmed by both the heterogeneity of the
symptom proﬁle and the lack of a diagnostic marker. A com-
mon endpoint, that includes aspects of DA dysfunction (Di Forti
et al., 2007; Murray et al., 2008; Howes and Kapur, 2009), remains
highly supported by the clinical evidence and allows for a spe-
ciﬁc outcome to investigate the etiology of the disease. However,
we postulate that a common DA endpoint may arise precisely
because it is central to the developmental pathology (Figure 1).
The dopaminergic system is one of the most organized neuro-
transmitter systems in the brain and is fundamental for a range
of functions involved in cognition, motivation and reward (Smith
andKieval, 2000; Aldridge et al., 2004; Nicola, 2007). Furthermore,
alterations in DA signaling have a range of cascading effects on
other neurotransmitter systems such as glutamate (e.g., NMDA)
and GABA. Therefore, even small alterations in DA function or
organization have the potential to lead to complex cognitive out-
comes when coupled with other general and variable insults such
as altered genetic architecture, drug use, stress or adolescent mat-
uration. In addition, these secondary stressors may individually
produce differing phenotypes and thus heterogeneity in symptom
proﬁle.
Our work the in DVD-deﬁcient rat model suggests that the
developmental absence of this ligand produces discrete alter-
ations in how DA systems develop. Alterations in DA speci-
ﬁcation factors (Cui et al., 2010) and DA metabolism (Kesby
et al., 2009) induced by DVD deﬁciency could have lasting
inﬂuences on the DA signaling. Additionally, these animals
show behavioral sensitivities to psychomimetic drugs at adult-
hood (Kesby et al., 2006, 2010, 2011; O’Loan et al., 2007) which
model at least the positive symptoms of schizophrenia (Laruelle
and Abi-Dargham, 1999; Lahti et al., 2001). Moreover, another
developmental model, that utilizes PolyI:C to mimic prenatal
infection, also shows alterations in Nurr 1, and similar behav-
ioral sensitivities to these psychomimetic drugs in adulthood
(Meyer et al., 2008; Vuillermot et al., 2010). Taken together this
suggests that vastly differing developmental insults can cause sim-
ilar phenotypes and perhaps even converge on common early
mechanisms (Eyles et al., 2012). Thus a network of small com-
munication errors, perhaps via the interaction of a variety of
key receptors (RXR, VDR, Nurr1, Ret) result in an altered
developmental landscape. This may lead to an altered number
of DA neurons after perinatal cell death events or altered DA
functionality/connectivity.
The data amassed in the DVD-deﬁcient rat suggest that sub-
tle developmental alterations in DA function can lead to an
altered adult behavioral phenotype. Moreover, utilizing differing
developmental insults, animal models have demonstrated similar
developmental dopaminergic abnormalities and adult behavioral
phenotypes. Therefore, schizophrenia may be a disorder occur-
ring via genetic or environmental factors that features a common
early disruption in DA development. The emerging data suggest-
ing that alteredDA functionprecedes the onset of psychosis further
suggests that dopaminergic abnormalities are not a byproduct
of psychosis but rather a latent signal of altered DA develop-
ment. Thus, altered dopaminergic function in schizophrenia may
represent a potential biological marker and even a target for
intervention.
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FIGURE 1 |Temporal profile of developing schizophrenia symptoms. Early
alterations in dopamine development due to genetic, environmental or a
combination of both lead to abnormalities in dopamine function (positive
symptoms) and subsequent alterations in other neurotransmitter systems
(negative symptoms). During adolescence and the prodromal phase
of the disease clear changes in dopamine function can be observed.
Frank psychosis and disease onset are directly related to dopaminergic
function and can be effectively treated. The lack of effect of antipsychotic
treatment on persisting negative symptoms suggest they are not
directly related to dopamine function. Rather, they represent the
downstream consequence of early dopamine dysfunction or the
extraneous effects of speciﬁc genetic and environmental risk factors
on other neurotransmitter systems such as glutamate and GABA.
These non-speciﬁc actions, outside of the core schizophrenia etiology,
result in a large heterogeneous proﬁle of negative symptoms in
patients.
CONCLUSION
Schizophrenia is an extremely complex disorder. We are not sug-
gesting that future therapeutic interventions be limited to a simple
“ﬁx DA early and ﬁx schizophrenia” interpretation. However,
observations in the DVD-deﬁcient rat, alternative animal models
and existing clinical evidence suggests that a core/common fea-
ture may be early DA dysfunction. That this could originate from
an early alteration in DA development is not a radical premise
but the concept itself is extremely hard to assess in humans
for a variety of obvious temporal and ethical reasons. However,
understanding how the potential cascade of events after early
alterations in DA neuron development inﬂuence other neuro-
transmitter systems in animal models, such as the DVD-deﬁcient
rat, may increase our understanding of the actual etiology of
schizophrenia. Furthermore, subtle alterations to DA develop-
ment may provide a platform to learn and understand the variable
outcomes associated with a range of “second-hit” targets. The
future of basic schizophrenia research should be focused on
early dopaminergic development with the goal of further under-
standing existing and underlying abnormalities in schizophrenia
patients that may, in turn, direct treatment solutions in the
clinic.
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